Waregem (Belgium), 3 December 2009 - Pursuant to the Belgian legislation of 2 May 2007 relating to the disclosure of major shareholdings in listed companies, Arseus reports that it has received the following notifications.
On 30 November 2009, Arseus was informed by Waterland Private Equity Investments BV and EnHold NV that the 25% disclosure threshold as set out in the articles of association was exceeded by the latter on 25 November 2009. EnHold NV's ultimate shareholder is Waterland Private Equity Fund IV CV. As fund manager of Waterland Private Equity Fund IV CV and ultimate manager of the Waterland entities, Waterland Private Equity Investments BV exercises the voting rights in EnHold NV (at its sole discretion). Therefore Waterland Private Equity Investments BV is deemed to have ultimate control.
On 1 December 2009, Arseus NV was informed by Omega Pharma NV, Couckinvest NV and Marc, Chloé and Alysée Coucke that on 25 November 2009 Omega Pharma NV and Couckinvest NV respectively sold 7,500,000 and 330,000 Arseus shares.
Based on the denominator of 31,195,121 (total number of voting rights) and the relevant notifications, the shareholder structure of Arseus is as follows:
|
|
Number of shares |
Percentage of total |
|
EnHold NV |
7,830,000 |
25.10% |
|
Couckinvest NV/Coucke |
3,528,080 |
11.31% |
|
Fortis Investment Management SA |
2,756,357 |
8.84% |
|
Arseus NV (treasury shares) |
973,915 |
3.12% |
|
Public |
16,106,769 |
51.63% |
The original notifications are also available on the corporate website (www.arseus.com).
In case of any discrepancy between the English translation and the original Dutch version of this press release, the latter shall prevail.
Please open the link below for the full press release:
